An extended-release or split-dose regimen could, in theory, improve overnight brain exposure and enable target engagement at lower total daily dose. However, this remains a PK/PD speculation without human dementia biomarker support, so it is better deferred until any clinical pharmacodynamic signal is established.
Curated pathway from expert analysis
flowchart TD
A["EIF2AK3; EIF2S1<br/>Hypothesis Target"]
B["Pathway Dysregulation<br/>Cited Mechanism"]
C["Cellular Response<br/>Stress or Clearance Change"]
D["Neural Circuit Effect<br/>Synapse/Glia Vulnerability"]
E["PD<br/>Disease-Relevant Outcome"]
A --> B
B --> C
C --> D
D --> E
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style B fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style E fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9aNo linked papers recorded for this hypothesis yet.
No curated PDB or AlphaFold mapping for EIF2AK3; yet. Search RCSB →
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for EIF2AK3; EIF2S1.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No resource usage or linked notebooks recorded for this hypothesis yet.
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF healthy elderly or early-AD participants receive oral EIF2AK3/EIF2S1 modulator at a total daily dose of X mg for 28 days in a within-subject cross-over design (immediate-release BID vs. extended-re | CSF biomarker of eIF2 pathway activation (e.g., p-eIF2α or downstream ATF4) will be significantly lower with nighttime extended-release exposure vs. same total | — no observation — | pending | 0.25 |
| IF a single-arm cohort of patients with biomarker-confirmed neurodegeneration (CSF t-tau/p-tau positive) receive escalating daily doses (low/mid/high) of a CNS-penetrant EIF2AK3/EIF2S1 pathway modulat | Pharmacodynamic ceiling effect: target engagement (CSF p-eIF2α reduction) reaches asymptotic maximum (±10%) at 40-60% of the highest tolerable dose, suggesting | — no observation — | pending | 0.20 |